When our skin is damaged, a whole set of biological processes springs into action to heal the wound. Now, researchers from the VIB-UGent Center for Inflammation Research have shown that one of the molecules involved in this, HMGB1, slows down wound healing. It is, however, also essential for tumor formation at sites of previous injury. The researchers found that HMGB1 controls the actions of neutrophils, a specific type of immune cells, in skin wounds and that this is crucial for cancer initiation. Targeting this pathway could be beneficial in diabetic wound care and in patients suffering from skin blistering diseases. Their work appears in Cell Reports.
27 November, 2019
Results of the survey, initiated by Merck and conducted by YouGov, indicated that there is a need to better educate people on the risk factors of type 2 diabetes, which can be prevented. The representative survey included over 9,000 people across 9 countries
14 November, 2019